Opus Genetics (IRD) Net Cash Flow Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Opus Genetics | 357.99 Mn | 298.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 35.47% |
| Dec 31, 2025 | -1.85% |
| Sep 30, 2025 | -64.99% |
| Jun 30, 2025 | -87.97% |
| Mar 31, 2025 | 111.57% |
| Dec 31, 2024 | -39.72% |
| Sep 30, 2024 | -57.46% |
| Jun 30, 2024 | -46.92% |
| Mar 31, 2024 | -4.96% |
| Dec 31, 2023 | 38.58% |
| Sep 30, 2023 | 46.39% |
| Jun 30, 2023 | 23.05% |
| Mar 31, 2023 | -6.99% |
| Dec 31, 2022 | 111.94% |
| Sep 30, 2022 | -41.22% |
| Jun 30, 2022 | -5.55% |
| Mar 31, 2022 | -37.09% |
| Dec 31, 2021 | -6.44% |
| Sep 30, 2021 | -42.41% |
| Jun 30, 2021 | 48.72% |
| Mar 31, 2021 | -88.75% |
| Dec 31, 2020 | 55.06% |
| Sep 30, 2020 | -15.47% |
| Jun 30, 2020 | 12.06% |
| Mar 31, 2020 | -18.27% |
| Dec 31, 2019 | 18.83% |
| Sep 30, 2019 | 15.18% |
| Jun 30, 2019 | 21.09% |
| Mar 31, 2019 | -16.24% |
| Dec 31, 2018 | -21.85% |
| Sep 30, 2018 | -16.03% |
| Jun 30, 2018 | 10.67% |
| Mar 31, 2018 | -12.91% |
| Dec 31, 2017 | 18.59% |
| Sep 30, 2017 | 12.54% |
| Jun 30, 2017 | -45.14% |
| Mar 31, 2017 | 9.10% |
| Dec 31, 2016 | 24.15% |
| Sep 30, 2016 | 16.83% |
| Jun 30, 2016 | 10.03% |
| Mar 31, 2016 | -49.66% |
| Dec 31, 2015 | 8.39% |
| Sep 30, 2015 | 26.58% |